Dieter David 4

What Happened
Dieter David, EVP & General Counsel of Collegium Pharmaceutical, received equity awards on February 10, 2026: 22,194 restricted stock units (RSUs) and 9,005 performance share units (PSUs) were reported as acquired (awarded) at $0.00. Concurrently, 2,781 shares were listed as disposed at $46.75 each to satisfy tax withholding obligations, a disposition valued at about $130,012. The awards are grants (not open‑market purchases) and the withholding is a routine tax-related disposition.

Key Details

• Transaction date(s): February 10, 2026 (filed February 12, 2026) — filing appears timely (filed within two business days).
• Awards: 22,194 RSUs and 9,005 PSUs granted/awarded at $0.00. The 9,005 PSUs were reported as having met performance-vesting criteria.
• Tax withholding: 2,781 shares withheld/disposed at $46.75 each for taxes (total ≈ $130,012). (Code F = tax withholding.)
• Vesting/schedule note: RSUs vest one‑third on Feb 10, 2027, with the remainder vesting in equal annual installments over the next two years, subject to continued service. PSUs were performance‑based and deemed achieved as of Feb 10, 2026.
• Additional note: Footnotes indicate 404 shares were acquired Jan 16, 2026 under the company ESPP.
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context

• RSUs/PSUs are grants representing contingent rights to receive shares if vesting conditions are met; they are not cash purchases and do not directly signal the insider buying stock.
• The 2,781‑share disposition is a common cashless/tax‑withholding action when awards vest — it reduces the net shares delivered to the insider to cover tax obligations.
• This filing documents compensation-related equity activity by an insider (not an open‑market buy or sale).